Smithkline Beecham Corporation

Glaxo Wellcome Inc.

Curt Dale Haffner

Patrick Reed Maloney

Darryl Lynn McDougald

Timothy Mark Willson

Stephen V Frye

Marcos Sznaidman

Millard Hurst Lambert, Iii

Michael Lawrence Sierra

James Martin Lenhard

Huaqiang Eric Xu

Amarjit Sab Randhawa

Robert Carl Andrews

Steven Michael Reister

Daniel David Sternbach

Cynthia Markert Cribbs

Esther Yu-Hsuan Chao

Istvan Kaldor

David Norman Deaton

Aaron Bayne Miller

Steven Anthony Kliewer

Julie Beth Stimmel

Jurgen M Lehmann

Derek James Parks

Steven Gerard Blanchard

Darryl Lynn Mcdougald

The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility 

Pyrrolidines as dipeptidyl peptidase inhibitors

The present invention relates to novel compounds, their use for inhibiting post prolin/analine-cleaving proteases, such as serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV), and to methods for their production and their therapeutic utility.

Fluoropyrrolidines as dipeptidyl peptidase inhibitors

The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR&#x3b1;, RXR&#x3b2;, or RXR&#x3b3;. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

Selective RXR ligands

The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility.

The present invention includes nuclear receptor heterodimer and nuclear receptor-coactivator peptide assays for identifying ligands for nuclear receptors, utilizing scintillation proximity and fluorescence resonance energy transfer (FRET), and methods of using identified ligands.

Use of FXR ligands

Activator of PPAR delta

Compounds of Formula (1) are disclosed. These compounds include selective activators of human PPAR delta.

Activators of PPAR delta

Substituted 6-azaandrostenones

Inhibitors of 5-.alpha.-testosterone reductase

Growing community of inventors

Durham, NC, United States of America

Curt Dale Haffner